Shanghai Xinpu BioTechnology

Shanghai Xinpu Biotechnology is a biopharmaceutical company specializing in the development of next-generation targeted protein degradation (TPD) therapies. Based in Shanghai's Zhangjiang Hi-Tech Park, the company focuses on discovering and developing molecular glues and PROTACs to address previously undruggable targets in oncology. Its lead program, XP-101, is a molecular glue degrader targeting GSPT1, currently in the pre-clinical stage for treating solid tumors and hematological malignancies. Founded in 2021, the company leverages its proprietary platform to create a robust pipeline of small molecule degraders aimed at high-value therapeutic targets.